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A B S T R A C T
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder of the liver metabolism due to
functional deficiency of the peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT). AGT deficiency
results in overproduction of oxalate which complexes with calcium to form insoluble calcium-oxalate salts in
urinary tracts, ultimately leading to end-stage renal disease. Currently, the only curative treatment for PH1 is
combined liver-kidney transplantation, which is limited by donor organ shortage and lifelong requirement for
immunosuppression. Transplantation of genetically modified autologous hepatocytes is an attractive therapeutic
option for PH1. However, the use of fresh primary hepatocytes suffers from limitations such as organ avail-
ability, insufficient cell proliferation, loss of function, and the risk of immune rejection. We developed patient-
specific induced pluripotent stem cells (PH1-iPSCs) free of reprogramming factors as a source of renewable and
genetically defined autologous PH1-hepatocytes. We then investigated additive gene therapy using a lentiviral
vector encoding wild-type AGT under the control of the liver-specific transthyretin promoter. Genetically
modified PH1-iPSCs successfully provided hepatocyte-like cells (HLCs) that exhibited significant AGT expression
at both RNA and protein levels after liver-specific differentiation process. These results pave the way for cell-
based therapy of PH1 by transplantation of genetically modified autologous HLCs derived from patient-specific
iPSCs.
1. Introduction
Primary hyperoxalurias (PHs) are rare inborn errors of glyoxylate
metabolism characterized by increased synthesis and excretion of the
end-product oxalate, and deposition of insoluble calcium oxalate in the
kidney and urinary tract (Harambat et al., 2011; Hoppe et al., 2009).
Primary hyperoxaluria type 1 (PH1, MIM 259900) is a rare autosomal
recessive metabolic disorder occurring in 1 per 120,000 live births. It is
caused by a functional deficiency of the liver-specific enzyme alani-
ne:glyoxylate aminotransferase (AGT, EC 2.6.1.44) encoded by the
AGXT gene (locus 2q37.3), which normally localizes to hepatocyte
peroxisome (Santana et al., 2003). AGT uses pyridoxal 5′-phosphate
(PLP) as a cofactor and catalyzes the nearly irreversible transfer of the
amino group from alanine to glyoxylate to yield pyruvate and glycine.
In PH1 patients, glyoxylate cannot be efficiently converted into glycine
and is instead oxidized to oxalate by lactate dehydrogenase, leading to
hyperoxaluria. Oxalate complexes with calcium in the urinary tract,
leading to the formation of insoluble calcium-oxalate salts. The salts
readily precipitate in tissues, resulting in kidney stones, kidney da-
mage/failure and injury to other organs, which accounts for all the
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pathological characteristics of PH1 including urolithiasis, ne-
phrocalcinosis and systemic oxalosis (Hoppe et al., 2009).
Therapeutic strategies aiming at either reducing oxalate production
or degrading excessive oxalate in the body would be beneficial for PH1
patients. In some patients, the disease process can be slowed by im-
plementation of hyper diuresis, low oxalate diet or supplementation
with vitamin B6, a precursor of pyridoxal phosphate (Cochat et al.,
2012). However, the only curative treatment for PH1 is combined liver-
kidney transplantation, which represents a form of enzyme replacement
therapy by restoring a normal hepatic AGT activity (Bergstralh et al.,
2010; Cochat et al., 2010). Nevertheless, this treatment is limited by
organ suitability, significant morbidity and mortality and the lifelong
requirement for immunosuppressive agents (Alonso and Ryckman,
1998; Newstead, 1998). Allogeneic hepatocyte transplantation has been
investigated as an alternative strategy (Beck et al., 2012; Jiang et al.,
2008) but it is unlikely to be successful because the high number of
engrafted hepatocytes required for clinical recovery of PH1 can hardly
be provided by this procedure. In addition, allogeneic hepatocyte
transplantation would still involve lifelong immunosuppression.
Given the limitations of current therapy and the severity of the
disease, PH1 is an attractive target for gene therapy, providing both a
long-lasting and less costly method for AGT delivery to the liver. In vivo
gene therapy experiments using either adenoviral vectors (Castello
et al., 2016; Salido et al., 2006) or adeno-associated virus vectors
(Salido et al., 2011) encoding the human AGT yielded encouraging
results in AGXT−/− mice. Nevertheless, long-term correction using
non-integrative viral vectors involves iterative injections of vectors,
potentially leading to cytotoxicity and immunotoxicity. This pitfall may
be overcome by an alternative approach based on ex vivo genomic in-
tegration of the wild-type human AGXT gene into hepatic cells using
lentiviral vectors (LVs). LVs are suitable tools for gene therapy by virtue
of their ability to stably integrate into the target cell genome and the
absence of pre-existing humoral and cellular immunity against vector
components in most humans. Moreover, the liver cell transduction ef-
ficacy of LVs has been demonstrated in numerous studies, notably in the
field of hemophilia gene therapy (Annoni et al., 2013; Cantore et al.,
2015; Ohmori et al., 2018), while tissue-specific vector expression can
be achieved by addition of internal promoters to HIV-1-derived vectors
exhibiting partially deleted LTR sequences (Moreau-Gaudry et al.,
2001; Zufferey et al., 1998). Ideally, LVs should target primary human
hepatocytes, but the invasiveness of liver biopsies along with the poor
growth activity and lifespan of hepatocytes in primary culture limit
their use in vitro (Fukuda et al., 2017; Laurent et al., 2010). The recent
advent of hepatocyte-like cells (HLCs) derived from human induced
pluripotent stem cells (iPSCs) (Takahashi et al., 2007) represents an
attractive alternative to primary human hepatocytes. Indeed, the ca-
pacity of patient-specific iPSCs to differentiate into genetically similar
somatic cell types allows the generation of a substantial quantity of
patient-specific cells, including hepatocytes, for use as in vitro models
for disease modeling and toxicological studies, as well as cell or gene
therapy (Gao and Liu, 2017; Takayama et al., 2018; Zhang et al., 2011).
In this study, we successfully generated iPSCs derived from a
homozygous PH1 patient (PH1-iPSCs) harboring a c.731 T > C muta-
tion (p.I244T) in exon 7 of AGXT gene, which is the second most
common mutation accounting for PH1 (Santana et al., 2003). Further-
more, we demonstrate for the first time the therapeutic genome mod-
ification of HLCs derived from PH1-iPSCs, after transduction with a
liver-specific lentiviral vector expressing wild-type AGXT cDNA. These
results will contribute to the proof-of-principle of PH1 regenerative
medicine, based on the transplantation of autologous HLCs derived
from iPSCs.
2. Material and methods
2.1. Cell culture
Cryopreserved primary human fibroblasts were obtained from skin
punch biopsies of a healthy volunteer and a PH1-diagnosed patient
harboring the homozygous c.731 T > C mutation (p.I244T) in exon 7
of the AGXT gene. We obtained written informed consent from both
participants. Cells were thawed and cultured for one week on 0.1%
gelatin-coated culture plates (Sigma-Aldrich) in complete Dulbecco's
Modified Eagle Medium (DMEM) (Life Technologies) containing 10%
fetal bovine serum (FBS, Eurobio) and 100 UI/ml penicillin/strepto-
mycin (P/S, Hyclone) before reprogramming. The human hepatoma
(HepG2 and Huh7) and human embryonic kidney 293 T (HEK293T) cell
lines were maintained in complete DMEM. The human myelogenous
K562 cell line was maintained in Roswell Park Memorial Institute
medium (RPMI) (Life Technologies), supplemented with 10% FBS and
100 UI/ml P/S.
2.2. Human iPSC culture
Fibroblast-derived iPSCs free of reprogramming transgene were
generated by transducing wild-type (WT)- and PH1-fibroblasts with
Sendai viral (SeV) particles (Ban et al., 2011) using the CytoTune®-iPS
2.0 Sendai Reprogramming Kit (Invitrogen) according to the manu-
facturer's instructions. Briefly, fibroblasts were transiently exposed to
SeV particles for 20 h at 37 °C and cultured for six additional days in
fibroblast culture media. Cells were then transferred onto a feeder layer
of mitomycin-inactivated mouse embryonic fibroblasts (MEFs) at mul-
tiple densities (850, 1700 and 3400 cells/cm2) and cultivated in
KnockOut DMEM/F12 (Life Technologies) containing 20% KnockOut™
Serum Replacement (KOSR, Life Technologies), 1% non-essential amino
acids (Life Technologies), 1% GlutaMAX (Life Technologies), 0.5 mM
sodium butyrate (Sigma-Aldrich), 0,1mM beta-mercaptoethanol (Life
Technologies), 50 μg/ml L-Ascorbic acid 2-phosphate sesquimagnesium
salt hydrate (Sigma-Aldrich), 10 ng/ml basic fibroblast growth factor
(Peprotech) and 100 UI/ml P/S. Four weeks after transduction, emer-
ging iPSC colonies were individually picked up and expanded onto MEF
monolayer. Two WT- and two PH1-iPSC clones were further selected on
the basis of typical undifferentiated stem cell morphology (high nu-
cleus-to-cytoplasm ratio, defined borders and prominent nucleoli). Se-
lected iPSC clones were finally transferred onto feeder-free Cellartis®
DEF-CS™ Culture System (Takara Bio Europe), therefore exhibiting
proliferation as monolayer iPSC lines with continuous passaging twice a
week, as previously described (Asplund et al., 2016).
2.3. Genomic DNA extraction and amplification
Genomic DNA was isolated using the NucleoSpin® Tissue kit
(Macherey-Nagel) according to the manufacturer's instructions and
were PCR-amplified using specific primers (online Supplemental
Table 1). For fibroblast and iPSC genotyping, PCR products from the
AGXT exon 7 were analyzed by Sanger sequencing. To assess lentiviral
cassette integration into iPSC and HepG2 genome, we designed specific
primers to amplify the region overlapping the AGXT or eGFP cDNA
sequence and the WPRE sequence (online Supplemental Table 1).
2.4. RNA extraction and RT-PCR analysis
Total RNA was isolated using NucleoSpin® RNA kit (Macherey-
Nagel) and cDNA was synthesized using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems™) according to the
manufacturer's instructions. Cellular expression of pluripotency-asso-
ciated markers and Sendai reprogramming factors, as well as lentiviral
cassette expression, were analyzed by RT-PCR using specific primers
(online Supplemental Table 1). We used specific primer sets to
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distinguish specifically between endogenous and exogenous AGXT ex-
pression. Exogenous AGXT expression was specifically detected using
primer sets located in the 3′ region of the AGXT cDNA and the 5′ region
of the WPRE sequence (Fig. 4A). Endogenous AGXT expression was
specifically detected using a forward primer located in exon 10 (coding
region) of the endogenous AGXT gene and a reverse primer located in
exon 11 (3’UTR region) of the endogenous AGXT gene. A semi-quan-
titative real-time PCR (RT-qPCR) assay was used to quantify hepatic
markers, endogenous and exogenous AGXT expression using the
GoTaq® qPCR Master Mix kit (Promega); relative gene expression was
normalized to endogenous human ribosomal protein lateral stalk sub-
unit P0 (HuPO) mRNA.
2.5. Alkaline phosphatase activity and immunocytofluorescence
iPSCs were challenged for alkaline phosphatase activity using the
Leukocyte Alkaline Phosphatase Kit (Sigma-Aldrich), according to the
manufacturer's instructions. For immunocytofluorescence analysis, cells
were fixed for 15min at 4 °C in 4% paraformaldehyde and then washed
three times in PBS containing 0,2% Triton X-100 for permeabilization.
Cells were blocked in PBS/0,2% Triton X-100/1% human serum al-
bumin (HSA) for 1 h at 4 °C, washed three times with PBS/1% HSA and
incubated overnight at 4 °C with primary antibodies diluted at working
concentration in PBS/0,2% Triton X-100/1% HSA. After incubation,
cells were washed three times with PBS/1% HSA and incubated for 1 h
at room temperature with secondary antibodies diluted at working
concentration in PBS/0,2% Triton X-100/1% HSA. Cells were washed
twice with PBS and finally incubated with 1×4,6-diamidino-2-2-phe-
nylindole (DAPI) for 15min at room temperature. The primary and
secondary antibodies used in this study are listed online (Supplemental
Table 2). Images were captured with an inverted fluorescence micro-
scope (Nikon Eclipse Ti microscope).
2.6. Teratoma formation and analysis
Teratomas were obtained after injecting 1×106 WT- or PH1-iPSCs
suspended in extracellular matrix gel (Sigma-Aldrich, St-Louis, MO) in
the subcutaneous neck region of immunodeficient NSG mice (NOD Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, animal facilities A2, University of
Bordeaux, France). Tumors were harvested 6 weeks after injection and
fixed in 4% paraformaldehyde. Tissues were paraffin-embedded, sec-
tioned and stained with hematoxylin and eosin (HE), and alcian blue.
All animal procedures were approved by the Institutional Animal Care
and Use Committee of Bordeaux University.
2.7. Karyotype analysis
WT- and PH1-iPSCs were cultured to 80% confluence in 6-well
plates. After synchronization with bromodeoxyuridine, thymidine ki-
nase and colcemid, cells were trypsinized with trypsin/EDTA (0,05%/
0,2%) (Fisher Scientific), treated with 0.075M KCl and prefixed with
1ml of fixative solution composed of Methanol/Acetic Acid (3:1) and
resuspended in 10ml of fixative solution. Cells were centrifuged for
6min at 200 g before final resuspension in 5ml of fixative. Standard R-
banding analysis was performed on metaphases obtained from iPSC
clones. At least 20 metaphases were fully karyotyped with the help of
an automated imaging system (MetaSystems).
2.8. Lentiviral vectors and cell transduction
Self-inactivated (SIN) lentiviral vectors derived from the previously
described pRRL-MND-MCS-WPRE lentivector (Richard et al., 2004).
Lentiviral vectors harbored the optimized human AGXT cDNA (Mesa-
Torres et al., 2014) or eGFP cDNA under control of the murine trans-
thyretin promoter (TTRp) fused to a synthetic hepatocyte-specific en-
hancer to direct liver-specific expression (Nguyen et al., 2005). The
modified retroviral MND promoter was used to drive ubiquitous ex-
pression of AGXT and eGFP transgenes (Richard et al., 2004). VSV-G-
pseudotyped recombinant lentiviral particles were produced by triple-
transient transfection of three plasmids in 293 T cells: the transfer
vector plasmid, the packaging plasmid pCMVΔR8.91, and the VSV-G
envelope protein-coding plasmid pMD.G as described (Bedel et al.,
2012). Titers of eGFP-expressing vectors were determined after serial
dilutions in HepG2 hepatoblastoma cell lines. Titers of AGXT-con-
taining lentivectors were estimated on the basis of p24 antigen levels
determined by ELISA assay in the viral supernatant (Innotest HIV p24,
INGEN SA, Rungis, France), by comparison with that of simultaneously
produced eGFP vectors as previously described (Richard et al., 2004).
Lentiviral vector supernatants were tested for the absence of replica-
tion-competent virus. To evaluate tissue-specific expression of lentiviral
vectors, hepatic (Huh7, HepG2), epithelial (HEK293T) and myelo-
genous (K562) human cell lines, as well as primary human fibroblasts
and WT-iPSCs, were transduced with lentiviral vectors at a low multi-
plicity of infection (m.o.i. = 1) to obtain proviral integration of around
one copy/cell. In additive gene therapy experiments, iPSCs from the
PH1 patient were transduced at a multiplicity of infection of 5.
2.9. Flow cytometry analysis
At day 7 post-lentiviral transduction, eGFP fluorescence was ana-
lyzed using FACSCanto™ II (BD Biosciences) and FACSDiva™ software
(BD Biosciences).
2.10. In vitro differentiation of iPSCs toward hepatic lineage
Feeder-free cultured iPSCs were differentiated into hepatocyte-like
cells (HLCs) by applying a serum- and feeder-free procedure re-
capitulating liver development, as previously described (Asplund et al.,
2016; Ghosheh et al., 2016). First, iPSCs were guided to differentiate
into definitive endoderm cells (DECs) using the Cellartis® Definitive
Endoderm Differentiation Kit (Takara Bio Europe), according to the
manufacturer's instructions. At day 7, the DECs were enzymatically
dissociated with TrypLE™ Select Enzyme (Life Technologies), reseeded
into appropriate cell culture vessels, and differentiated into HLCs using
the Cellartis® Hepatocyte Differentiation Kit (Takara Bio Europe), ac-
cording to the manufacturer's instructions.
2.11. Assay for cytochrome P450 activity
Cytochrome P450 3A4 (CYP3A4) activity was measured in iPSCs
and HLCs by using the P450-Glo™ CYP3A4 Assay kit (Promega) ac-
cording to the manufacturer's instructions. Briefly, cells were incubated
for 1 h at 37 °C with respective cell culture media containing 3 μM of the
CYP3A4 substrate luciferin isopropyl acetal (proluciferin). After in-
cubation, 25 μl of culture media were transferred from each well to a
96-well opaque white luminometer plate. Next, a luciferin detection
reagent (25 μl) was added to the samples to initiate a luminescent re-
action. The plate was incubated at room temperature for 20min, and
luminescence was measured using a GloMax® Multi Detection System
luminometer (Promega). Luminescence signal was standardized for
each well by cell protein content determined by the Pierce™ BCA
Protein Assay Kit (ThermoScientific), according to the manufacturer's
instructions.
2.12. Western blot
Total cellular protein extraction was carried out using T3EN buffer
(10mM Tris base, 150mM NaCl, 3 mM EDTA, H2O) and SB2X buffer
(4% SDS, 20% glycerol, 50mM Tris-HCl pH 6.8, H2O), followed by
10min incubation at 100 °C. Protein concentration was determined
with the Pierce™ BCA Protein Assay Kit (ThermoScientific), according
to the manufacturer's instructions. Respectively 20 μg and 1 μg of
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protein from HLC and HepG2 lines were separated by electrophoresis
on 12% (w/v) acrylamide SDS-PAGE and transferred onto a poly-
vinylidene difluoride Immobilon-P membrane (Millipore Corp.). The
blot was blocked with TBS (20mM Tris-HCl pH 7.6, 136mM NaCl)
containing 5% skimmed milk, and then incubated at 4 °C overnight with
primary antibodies diluted at working concentration in TBS containing
5% bovine serum albumin (BSA, Sigma-Aldrich). The following day, the
membrane was washed three times for 5min in TBS with 0.1% Tween
20 (TBS-T) and then incubated with horseradish peroxidase-linked
secondary antibodies diluted at working concentration in TBS-milk for
1 h at room temperature. The membrane was washed a further three
times for 5min with TBS-T before developing using the Amersham ECL
Prime Western Blotting Detection Reagent kit (GE Healthcare), ac-
cording to the manufacturer's instructions. Images were captured with
the LAS-3000 Imager (Fujifilm). Relative expression was determined by
density measurement and standardized as the ratio AGT signal /GAPDH
signal using ImageJ software. The primary and secondary antibodies
used for western blotting are listed in online Supplemental Table 3.
2.13. AGT enzymatic assay
The AGT enzymatic activity was determined by incubating 500 to
1000 μg of soluble lysate with L-alanine (50mM) and glyoxylate
(50mM) for 2 h in the presence of pyridoxal-phosphate (50 μM) in
100mM potassium phosphate buffer, pH 7.4. The reaction was stopped
with perchloric acid 1M and neutralized with morpholinopropanesul-
phonic acid (Mops 0.2M). Pyruvate formation was measured by the
spectrophotometric assay after incubation with lactate deshydrogenase
(LDH) and NADH (0.22mM) in Tris-Cl 0.37M pH 8.3 solution.
2.14. Statistical analysis
Values shown represent the mean ± SD (n=3 to 4 independent
experiments). P-values were determined using a one-way analysis of
variance (ANOVA) complemented by Tukey's multiple comparisons test
to examine significance across comparisons. Difference was considered
significant at p < 0.05.
3. Results
3.1. Generation and characterization of iPSCs from PH1 patient-derived
dermal cells
Skin fibroblasts were isolated from a healthy volunteer and a PH1-
diagnosed patient harboring the homozygous c.731 T > C mutation
(p.I244T) in exon 7 of AGXT gene (Fig. 1A). WT- and PH1-iPSC lines
were generated in vitro from primary fibroblasts after transduction with
a modified, non-transmissible form of Sendai Virus (SeV) particles
carrying the reprogramming factors SOX2, OCT3/4, c-MYC and KLF4,
which is sufficient for efficient reprogramming (Takahashi et al., 2007).
The exclusive cytoplasmic expression of SeV particles allows the gen-
eration of iPSCs free of reprogramming transgenes, as confirmed by RT-
PCR analysis. SeV structural genome and exogenous reprogramming
transgene expression was detected exclusively in transduced primary
fibroblasts (Sendai fibroblasts), whereas non-transduced fibroblasts and
iPSC lines (at 18–19 passages) harbored neither SeV genome nor re-
programming transcript expression (Fig. 2A).
iPSCs were established and expanded as individual colonies onto
MEFs for 12 weeks. Two isolated WT-iPSC clones (hereinafter named
WT-iPSC#1 and WT-iPSC#2) and two isolated PH1-iPSC clones (here-
inafter named PH1-iPSC#1 and PH1-iPSC#2) were switched to feeder-
free culture conditions using the Cellartis® DEF-CS™ Culture System,
which allows enzymatic passaging of pluripotent stem cells and ex-
pansion as monolayer iPSC lines. We confirmed the stability of the
AGXT genotype in all established iPSC lines (Fig. 1B, WT-iPSC#2 and
PH1-iPSC#2 and online Supplemental Fig. S1, WT-iPSC#1 and PH1-
iPSC#1).
Feeder-free WT and PH1-iPSC lines exhibited undifferentiated stem
cell morphology with a high nucleus/cytoplasm ratio and prominent
nucleoli (Fig. 2B, WT-iPSC#2 and PH1-iPSC#2 and online Supple-
mental Fig. S2, WT-iPSC#1 and PH1-iPSC#1). Moreover, all iPSC
clones expressed endogenous pluripotency-associated markers (OCT3/
4, SOX2, NANOG, REX1, ESG1, DPPA4, hTERT, KLF4, c-MYC), as de-
monstrated by alkaline phosphatase activity, immunocytofluorescence
(Fig. 2B, WT-iPSC#2 and PH1-iPSC#2 and online Supplemental Fig. S2,
WT-iPSC#1 and PH1-iPSC#1) and RT-PCR analysis (Fig. 2C). We de-
tected endogenous expression of KLF4 and c-MYC genes by RT-PCR
analysis in primary fibroblasts as previously described (Takahashi et al.,
2007). We then generated teratoma by subcutaneous injection of
1×106 cells from all WT- and PH1-iPSC lines into 2-month-old im-
munodeficient NSG mice. About 6 weeks after injection, tumors ex-
hibited goblet cells (endoderm), chondrocytes (mesoderm) and neu-
roectoderm and pigmented tissue (ectoderm), which demonstrates the
ability of iPSCs to differentiate into all three germ layers (Fig. 3A).
Finally, karyotype analyses by R-banding studies confirmed the absence
of macroscopic genetic abnormality in WT- and PH1-iPSC lines (Fig. 3B,
WT-iPSC#2 and PH1-iPSC#2 and online Supplemental Fig. S3, WT-
iPSC#1 and PH1-iPSC#1). Therefore, we have successfully committed
Fig. 1. Analysis of AGXT mutations in primary fibroblasts and iPSCs.
The homozygous c.731 T > C AGXT mutation was detected in PH1-fibroblasts (A) and PH1-iPSC lines (B) by Sanger sequencing of AGXT exon 7.
J. Estève, et al. Stem Cell Research 38 (2019) 101467
4
WT- and PH1-fibroblasts in pluripotent stem cells free of reprogram-
ming transgenes that display human embryonic stem cell-like features.
3.2. Lentiviral-mediated delivery of therapeutic AGT in PH1-iPSCs
To trigger wild-type AGT expression in the PH1-iPSC line, we de-
signed a third-generation lentiviral vector (LV) carrying a full-length
codon-optimized human AGXT cDNA. Lentiviral constructs carried the
modified retroviral MND promoter or the liver-specific transthyretin
promoter (TTRp) to drive ubiquitous or liver-specific expression of the
therapeutic (AGXT) or control (eGFP) transgenes, respectively (Fig. 4A).
We confirmed ubiquitous and specific expression toward the hepatic
lineage after lentiviral transduction of both hepatic (HepG2 and Huh7)
and non-hepatic (HEK293T, K562, WT-fibroblast and WT-iPSC#2) cell
lines at low multiplicity of infection (m.o.i=1) (Fig. 4B). As expected,
MNDp-eGFP lentivector was expressed in each of the different cell lines,
while TTRp-eGFP lentivector was selectively expressed in hepatic cells.
We then investigated lentiviral vector-mediated AGXT and eGFP
expression in HepG2 cells transduced with the corresponding lenti-
vectors at m.o.i of 5. Once HepG2 genomic integration of the cassettes
had been confirmed (Fig. 4C), we observed significant lentiviral vector-
mediated transgene expression in transduced HepG2 cells by RT-PCR
(Fig. 4D) and western blotting analysis (Fig. 4E). RT-PCR analysis re-
vealed transcriptional expression of TTRp-AGXT and TTRp-eGFP cas-
settes limited to transduced HepG2 lines, while the endogenous AGXT
gene was expressed in all conditions (Fig. 4D). Similarly, western
blotting analysis using a primary antibody detecting indistinctly both
endogenous and exogenous (derived from TTRp-AGXT cassette) AGT
revealed basal expression of endogenous AGT in both non-transduced
HepG2 and HepG2-TTRp-eGFP lines, while the HepG2-TTRp-AGXT line
exhibited a 5-fold increased global AGT expression vs no-transduced
HepG2 (Fig. 4E). Finally, we obtained ~5-fold increased AGT enzy-
matic activity in HepG2-TTRp-AGXT as compared with HepG2 cell
lines, demonstrating the functional activity of our therapeutic hepatic-
specific lentivector (Fig. 4F). These results confirmed therapeutic AGT
expression at both transcript and protein levels in the hepatic HepG2
cell line after transduction with the therapeutic TTRp-AGXT lentiviral
vector.
We then performed genome modification of PH1-iPSCs by trans-
duction with TTRp-AGXT or TTRp-eGFP lentivector at m.o.i. of 5. We
preferentially targeted PH1-iPSC#2 because we observed sustained
proliferation and maintenance of stem-cell morphology characteristics
through passages of this clone (data not shown). PCR analysis con-
firmed genomic integration of lentivectors into transduced iPSC lines,
referred to as PH1-iPSC#2-TTRp-AGXT and PH1-iPSC#2-TTRp-eGFP
lines, respectively (Fig. 4F).
Fig. 2. Generation and characterization of human WT and PH1-iPSCs.
(A) RT-PCR analysis of Sendai virus (SeV) reprogramming factor expression before SeV transduction (Fibroblast), 5 days after SeV transduction (Sendai fibroblast)
and in established iPSCs (iPSC line). (B) Analysis of iPSC morphology (BF, bright field), alkaline phosphatase activity (ALP) and pluripotency-associated marker
expression (green immunofluorescence staining) in iPSCs expanded on stromal MEF cells (colony) or in feeder-free conditions (monolayer). DAPI staining revealed
nuclei (blue). Scale bars, 100 μm. Magnification, 100X. (C) RT-PCR analysis of endogenous pluripotency-associated marker expression in iPSC lines as compared with
primary fibroblasts. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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3.3. AGT rescue in iPSC-derived hepatocyte-like cells transduced with
TTRp-AGXT lentivector
We next proceeded to in vitro differentiation of WT-iPSC#2, PH1-
iPSC#2, PH1-iPSC#2-TTRp-AGXT and PH1-iPSC#2-TTRp-eGFP lines
into hepatocyte-like cells (HLCs), respectively named WT-HLC#2, PH1-
HLC#2, PH1-HLC#2-TTRp-AGXT and PH1-HLC#2-TTRp-eGFP. We
used a protocol simulating normal liver development in three main
phases: definitive endoderm, hepatic progenitors and hepatocyte-like
cells. During the first phase, we used the Cellartis® Definitive Endoderm
Differentiation medium to differentiate iPSCs into a monolayer culture
of definitive endoderm cells (DECs), which represent the earliest pre-
cursors of all endodermal organs; namely, liver, pancreas, lung, gut and
thyroid (Hannan et al., 2013). Whereas iPSC lines showed typical em-
bryonic stem cell morphology prior to the differentiation process, they
progressively exhibited spiky or triangular shapes, a typical mor-
phology of DEC reaching confluence (Fig. 5A). We confirmed definitive
endoderm commitment by immunofluorescence detection of the
specific endodermal marker SOX17 at day 7 of differentiation (Fig. 5A).
During the second phase, we guided DECs to subsequent hepatoblast
and HLC differentiation for 3 weeks in Cellartis® Hepatocyte
Differentiation medium. The cellular morphology progressively
changed during the differentiation process to finally reach typical he-
patocyte-like polygonal shape with canaliculated borders from day 21
of differentiation (Fig. 5A). Immunofluorescence analysis confirmed
hepatic cell commitment, as demonstrated by the specific expression of
the hepatic markers HNF4a and alpha-fetoprotein (aFP) in HLC by day
14 and day 21 of differentiation respectively. By day 31, we compared
the expression profile of several hepatic markers (albumin, aFP, alpha-1
antitrypsin (a1AT) and HNF4a) between iPSC lines, iPSC-derived he-
patocyte-like cells, primary fetal hepatocytes and primary adult hepa-
tocytes (Fig. 5B). Although we observed evidence of liver-specific ex-
pression in HLCs generated in our culture system, we acknowledge that
these cells were not terminally differentiated, as evidenced by re-
maining aFP expression. This observation is consistent with previous
studies demonstrating that pluripotent stem cell-derived hepatocyte-
Fig. 3. Teratoma and karyotype analysis.
(A) Alcian blue and hematoxylin/eosin staining of histological sections of a representative teratoma derived from WT-iPSC#2 and PH1-iPSC#2 shows tissues of all
three germ layers. Scale bars, 50 μm. Magnification, 40CX. (B) Representative karyotype analysis of WT-iPSC#2 (46, XX) and PH1-iPSC#2 (46, XY) revealed no
abnormalities. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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like cells more similarly mimic fetal rather than adult hepatocytes
(Baxter et al., 2015; Rashid et al., 2010). Detoxification activity of cy-
tochrome P450 3A4 (CYP3A4), which corresponds to the most abun-
dant CYP450 expressed in adult liver (Guengerich, 1999), was also
evaluated (Fig. 5C). CYP3A4 activity was significantly higher in HLCs
(25- to 40-fold increase) than in undifferentiated control iPSCs. Inter-
estingly, PH1-HLC#2 cell lines showed similar CYP3A4 activity, in-
dependently of the genetic modification (TTRp-AGXT, TTRp-eGFP,
mock), which suggests homogeneous hepatic differentiation.
We then analyzed the therapeutic benefit of AGXT additive gene
therapy in PH1-HLCs. We evaluated AGT rescue in PH1-iPSC-derived
HLC after transduction with TTRp-AGXT or TTRp-eGFP lentivectors.
RT-PCR analysis revealed transcriptional expression of TTRp-AGXT and
TTRp-eGFP lentivectors exclusively in PH1-HLC#2-TTRp-AGXT and
PH1-HLC#2-TTRp-eGFP respectively, while endogenous AGXT gene
was expressed in all HLC lines (Fig. 5D). On the other hand, AGT pro-
tein was detected only in WT-HLC#2 and PH1-HLC#2-TTRp-AGXT
cells, whereas PH1-HLC#2 and PH1-HLC#2-TTRp-eGFP exhibited no
endogenous AGT expression (Fig. 5E). These results suggest that the
mutant p.I244T AGT is unstable in HLCs and rapidly turns into non-
functional aggregates that are subsequently eliminated before reaching
hepatocyte peroxisome. Therefore, we hypothesize that WT-HLC#2
exhibited basal endogenous wild-type AGT expression, whereas the
AGT protein detected in PH1-HLC#2-TTRp-AGXT was entirely due to
the expression of the therapeutic TTRp-AGXT lentivector. Taken to-
gether, these results show that we have achieved the first successful
rescue of AGT by using liver-specific lentiviral vector in iPSC-derived
hepatocyte-like cells from a PH1 patient.
4. Discussion
PH1 is an inherited metabolic disease arising from the liver defi-
ciency of the AGT enzyme that leads to overproduction of oxalate,
which forms insoluble calcium salts in the kidney, resulting in ne-
phrocalcinosis and urolithiasis. Combined liver-kidney transplantation
is the only curative treatment for PH1 but it suffers from limitations,
which provides the impetus to develop innovative therapeutic options
such as liver-directed gene therapy. The recent advent of iPSCs has
opened up new avenues in the field of regenerative medicine, and the
availability of efficient hepatic differentiation procedures has made
iPSCs attractive for the treatment of liver diseases such as PH1 (Asplund
et al., 2016; Ghosheh et al., 2016; Hannan et al., 2013; Rashid et al.,
2010). In this study, we efficiently generated PH1-iPSCs free of repro-
gramming factors and expanded them under feeder-free conditions. We
then successfully differentiated in vitro PH1-iPSCs into hepatocyte-like
cells, which are suitable for disease modeling and gene therapy ex-
periments. Finally, we rescued AGT expression in PH1-iPSC-derived
HLCs after transduction with a self-inactivated liver-specific lentiviral
vector expressing an optimized AGT enzyme.
During the past decade, iPSCs have been generated with several
integrative and non-integrative methods, the former exploiting viral
vectors integrated in the host cell genome and stably expressing the
transgene, and the latter including any approach that enables transient
transgene expression in target cells. However, the persistence of re-
sidual transgene expression may alter the potential for iPSC differ-
entiation or induce malignant transformation (Okita and Yamanaka,
2011). Sendai vectors are the safest and most commonly used viral-
based approach to obtain iPSCs using non-integrative methods.
Furthermore, they allow the generation of iPSCs with much greater
efficiency than the conventional integrative vectors without influencing
the gene expression profile of the reprogrammed iPSCs (Trevisan et al.,
2017). In our study, we obtained an initial reprogramming efficiency on
feeder cells ranging from 0.002% to 0.08% for PH1- and WT-iPSCs
respectively, which corresponds to levels previously reported in the
literature (Ban et al., 2011).
Traditional biomedical research and preclinical studies frequently
rely on animal models that often fail to reproduce important clinical
phenotypes. Conventional cell lines are also frequently used but they
represent only a small number of cell types or diseases, and are char-
acterized by limited genetic diversity, rapid senescence and potentially
confounding immortalizing mutations. In recent years, human plur-
ipotent stem cells have attracted much attention, partly due to their
promising potential for modeling human diseases accurately. In this
study, we generated PH1-iPSCs from primary fibroblasts harboring the
AGXT c.731 T > C mutation, which is highly prevalent in Western
Europe, North Africa and the Middle East, as it has been reported in
around 20% of PH1 patients from these countries (Harambat et al.,
2010). To our knowledge, this is the first report of PH1-iPSC-derived
hepatocyte-like cells from a PH1 patient. In a previous study, primary
fibroblasts from a PH1 patient harboring the homozygous c.731 T > C
mutation in exon 7 of the AGXT gene were fully reprogrammed into
transgene-free iPSCs using the Sendai virus vector, but the potential for
hepatic differentiation was not demonstrated (Zapata-Linares et al.,
2016). The p.I244T AGT protein is known to be responsive to phar-
macological chaperones such as betaine (Santana et al., 2003), and we
believe that the combination of additive AGXT gene therapy and
pharmacological treatments could significantly improve the phenotype
of PH1 patients carrying the c.731 T > C mutation.
To facilitate the differentiation process and subsequent analysis of
the hepatocyte phenotype, we expanded WT- and PH1-iPSCs under
feeder-free conditions. To date, most pathophysiological studies of
AGXT mutations have been conducted in the stably transformed CHO-
GO cell line overexpressing glycolate oxidase (GO) and WT-AGT or
pathogenic variants (Dindo et al., 2018). We propose that HLCs derived
from PH1-iPSCs would offer new perspectives for the identification of
molecular defects associated with AGT mutations in liver cells. In the
future, the generation of iPSCs originating from a wide panel of PH1
patients and their differentiation into hepatocytes could play an im-
portant role in the exploration of phenotype/genotype correlations and
drug susceptibilities.
The present study goes further by demonstrating the stable genome
modification of hepatocyte-like cells derived from PH1-iPSCs, which
were previously transduced with a liver-specific self-inactivating len-
tiviral vector expressing wild-type AGXT cDNA. The AGXT sequence
was optimized for expression in human cells (Mesa-Torres et al., 2014)
and placed under the control of the liver-specific transthyretin pro-
moter, whose efficacy has already been demonstrated ex vivo and in vivo
in liver-disease animal models (Nguyen et al., 2005; Schmitt et al.,
2010). Importantly, we rescued AGT synthesis in PH1-HLC#2-TTRp-
AGXT following TTRp-AGXT lentiviral transduction, even though we
observed a lower AGT expression level than with WT-HLCs. This might
be due to the suboptimal expression of the transthyretin promoter and/
or incomplete differentiation state of iPSC-derived HLCs, as previously
reported (Baxter et al., 2015; Rashid et al., 2010; Roy-Chowdhury et al.,
2017). Integration of the therapeutic TTRp-AGXT lentiviral vector into
PH1-iPSCs allowed specific expression of AGT at both transcript and
Fig. 4. Characterization of the therapeutic AGT-expressing liver-specific lentiviral vector.
(A) Lentiviral vector construct and PCR primer location used for proviral integration analysis. (B) Analysis of eGFP expression in hepatic (HepG2 and Huh7) and non-
hepatic (HEK 293T, K562, WT-fibroblast and WT-iPSC#2) cells after lentiviral transduction. eGFP expression was detected by flow cytometry analysis and data were
expressed as means± SD of four independent experiments. (C) PCR analysis of proviral integration in transduced HepG2 cells. (D) RT-PCR analysis of eGFP and
AGXT expression in transduced HepG2 cells. (E) Western blotting analysis of AGT protein expression in transduced HepG2 cells. GAPDH was used as control
housekeeping gene. (F) PCR analysis of proviral integration in transduced PH1-iPSC#2 cells. Abbreviations: ns, non-significant; endo., endogenous.
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Fig. 5. Characterization of hepatocyte-like
cells (HLCs) and analysis of AGT expression
rescue.
(A) Bright field and immunofluorescence
staining of endodermic (SOX17) and hepatic
markers (HNF4a and aFP) throughout hepato-
cyte differentiation. Nuclei were localized by
DAPI (blue). Scale bars, 100 μm.
Magnification, 100X. (B) RT-qPCR analysis of
hepatic gene markers in HLCs at day 31 of
hepatocyte differentiation. Gene expression
was normalized to the endogenous HuP0 gene
and data are means± SD of four independent
experiments. (C) CYP3A4 activity analysis in
HLCs at day 31 of differentiation. Data were
expressed as means± SD of three independent
experiments; ٭, p < 0.05. (D) RT-PCR analysis
of eGFP and endogenous (endo. AGXT) or
exogenous AGXT expression in HLCs. (E)
Western blotting analysis of AGT protein ex-
pression in HLCs. ND; not determined.
Abbreviations: aFP, alpha-fetoprotein; a1AT,
alpha-1 antitrypsin; ns, non-significant; endo.,
endogenous. (For interpretation of the refer-
ences to colour in this figure legend, the reader
is referred to the web version of this article.)
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protein levels in differentiated hepatocyte-like cells. Furthermore, we
demonstrated the neutral effect of genome modification on the hepatic
differentiation process. However, caution is required regarding the
exhaustive consequences of genomic lentiviral integration. Despite
numerous safety improvements in lentiviral vectors (Cavazzana-Calvo
and Fischer, 2007), integration targeting is still challenging and inser-
tional mutagenesis cannot be strictly ruled out unless fully investigated.
For these reasons, strategies involving controlled genome modification
would be beneficial for establishing safer gene therapy protocols. Re-
cent advances in the field of targeted gene editing, mainly including
CRISPR/Cas9 system (Fineran and Charpentier, 2012; Jinek et al.,
2012), are likely to offer solutions. The efficacy of the targeted CRISPR/
Cas9 DNA break in enhancing therapeutic homology-directed repair has
been demonstrated in numerous studies, including hepatic diseases, and
could be a powerful alternative to viral vectors for PH1 gene therapy
(Lee et al., 2016; Pankowicz et al., 2017). However, we recently de-
monstrated that homology-directed repair is rare compared with NHEJ
pathway leading to on-target indels and unexpected chromosomal
truncations resulting from only one Cas9 nuclease-induced DSB by a
p53-dependent mechanism (Cullot et al., 2019). Base editing is a newer
genome-editing approach combining CRISPR systems together with
DNA modificating enzymes to directly introduce point mutations into
cellular DNA (Gaudelli et al., 2017). In recent studies, the authors were
able to efficiently convert targeted G·C base pairs to A·T without DNA
cleavage with high efficiency in human cells (Nishimasu et al., 2018).
This strategy would be applied to reverse the c.731 T > C mutation of
the AGXT gene responsible for hyperoxaluria in our PH1 patient.
5. Conclusion and/or summary
Human induced pluripotent stem cells can differentiate into hepa-
tocyte like-cells with the potential of clinical and experimental use for
inherited liver diseases. We generated PH1-iPSCs free of reprogram-
ming factors from a patient with primary hyperoxaluria type 1 and
demonstrated efficient hepatic lineage differentiation in vitro. In a gene
therapy experiment, we rescued AGT expression in hepatocyte-like cells
from PH1-iPSCs transduced with a therapeutic liver-specific lentiviral
vector. Taken together, our results pave the way for studying and cor-
recting primary hyperoxaluria type 1 using hepatocyte-like cells de-
rived from patient-specific induced pluripotent stem cells.
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